2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-159958
    KNa1.1-IN-2 3037315-44-6
    KNa1.1-IN-2 (Compound Z05) is a selective KNa1.1 channel inhibitor with blood-brain barrier penetration, particularly effective against the hERG channel. KNa1.1-IN-2 works by binding to the KNa1.1 channel and blocking the channel activity induced by Gain-of-function (GOF) mutations, effectively intervening in KCNT1-related epilepsy. Additionally, KNa1.1-IN-2 inhibits the GOF mutant Y796H. KNa1.1-IN-2 holds promise for research into KCNT1-related epilepsy disorders.
    KNa1.1-IN-2
  • HY-159972
    PKR1 antagonist 1 910113-60-9
    PKR1 antagonist 1 (PC1) is a potent PKR1 antagonist. PKR1 antagonist 1 reduces hyperalgesia and allodynia in SNI mice.
    PKR1 antagonist 1
  • HY-15997A
    (+)-U-50488 hydrochloride 114528-81-3
    (+)-U-50488 (hydrochloride) (+)-Trans-(1R,2R)-U-50488 hydrochloride) is a less active κ opioid receptor (KOR) agonist than the enantiomer of (-)-Trans-(1S,2S)-U-50488 (HY-15997).
    (+)-U-50488 hydrochloride
  • HY-159997
    AD353
    AD353 is a selective sigma-1 receptor ligand with antiallodynic activity. AD353 exhibits high potency both in a model of Capsaicin (HY-10448)-induced allodynia and in PGE2-induced mechanical hyperalgesia. AD353 exhibits a favorable pharmacokinetic profile.
    AD353
  • HY-160002
    MAO-B-IN-27 788824-83-9
    MAO-B-IN-27 (Compound 12c) is a monoamine oxidase B (MAO-B) inhibitor. MAO-B-IN-27 has potent and selective MAO-B inhibitory effect for hMAO-B with an IC50 values of 8.9 nM. MAO-B-IN-27 can be used for the research of parkinson's disease (PD).
    MAO-B-IN-27
  • HY-160081
    KCC2 Modulator-1 2704531-36-0
    KCC2 Modulator-1 (Example 52) is a KCC2 modulator with an EC50 value of 0.146 μM. KCC2 Modulator-1 can be used for the research of KCC2 mediated diseases.
    KCC2 Modulator-1
  • HY-160082
    KCC2 Modulator-2 2704531-37-1
    KCC2 Modulator-2 (example 53) is a KCC2 modulator with an EC50 of 0.215 μM. KCC2 Modulator-2 can be used in the study of neurological disorders.
    KCC2 Modulator-2
  • HY-160107
    AZ1422
    AZ1422 is a selective MCT4 inhibitor that can be used in cancer research.
    AZ1422
  • HY-160111
    PDM-042 1404488-48-7
    PDM-042 is a potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. PDM-042 shows potent inhibitory activities for human and rat PDE10A with IC50 values of less than 1 nM and more than 1000-fold selectivity against other phosphodiesterases. PDM-042 can be used for the research of schizophrenia.
    PDM-042
  • HY-160169
    Necrosis inhibitor 2 2258671-03-1
    Necrosis inhibitor 2 (Compound B19) is a cell necrosis inhibitor. Necrosis inhibitor 2 can be used to study diseases related to the necrosis pathway, including inflammation, tumors, metabolic diseases and neurodegenerative diseases.
    Necrosis inhibitor 2
  • HY-160189
    3-Ethyl-3-methylthiolan-2-one 103620-92-4
    3-Ethyl-3-methylthiolan-2-one is an antiepileptic agent that inhibits GABAA receptors.
    3-Ethyl-3-methylthiolan-2-one
  • HY-160207
    Elunetirom 2156649-32-8 99.24%
    Elunetirom (MA-JD21 )is a TR-β selective CNS-penetrant TR-β agonist prodrug and can be used for study of major depressive disorder (MDD).
    Elunetirom
  • HY-160426
    Gcase activator 3 2270984-21-7
    Gcase activator 3 (compound 9Q) is a glucosidase (Glucosidase, GCase) activator that can partially stabilize GCase and increase its activity. Gcase activator 3 reduces mutant GCase protein misfolding and degradation in fibroblasts and dopaminergic midbrain neurons. Gcase activator 3 can be used in the study of Parkinson's disease (PD) and related synucleinopathies.
    Gcase activator 3
  • HY-160481
    MG-1102 2567913-75-9
    MG-1102 is first-in-class dual binder of monomeric tau and pre-miRNA-146a. MG-1102 shows specific inhibition of miRNA146a with IC50s of 0.21 mM and 0.36 mM specific inhibition of doublelabeled pre-miRNA146a and mono-labeled pre-miRNA146a, respectively. MG-1102 interacts with tau monomers with a Kd of 3.21 mM by surface plasmon resonance (SPR). MG-1102 is a potential multi-target-directed ligands (MTDLs) for Alzheimer’s disease (AD).
    MG-1102
  • HY-160508
    NCX1-IN-1 2754283-55-9
    NCX1-IN-1 (Compound 6) is the inhibitor for Na+/Ca2+ exchanger(NCX).
    NCX1-IN-1
  • HY-160509
    BTB 06061 652967-47-0
    BTB 06061 is a TRPM7 inhibitor and can be used for study of ischemic disease.
    BTB 06061
  • HY-160529
    α7 nAChR Modulator-2
    α7 nAChR Modulator-2 (Compound 7b) is a α7 nAChR positive allosteric modulator (PAM) with an EC50 of 2.1 μM. α7 nAChR Modulator-2 can be used for the research of cognitive disorders.
    α7 nAChR Modulator-2
  • HY-160548
    mTOR inhibitor-18 2170358-67-3
    mTOR inhibitor-18 (Example 106) is a mTOR inhibitor. mTOR inhibitor-18 can be used for mTOR related research, such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
    mTOR inhibitor-18
  • HY-160588
    Nav1.8-IN-7 2761181-58-0
    Nav1.8-IN-7 (Example 116) is a selective Nav1.8 inhibitor. Nav1.8-IN-7 shows an inhibition of >50% with 100 nM for Nav1.8. Nav1.8-IN-7 inhibits hERG with an IC50 of 15.6 μM. Nav1.8-IN-7 has the potential for pain research.
    Nav1.8-IN-7
  • HY-160589
    Nav1.8-IN-8 2626945-23-9
    Nav1.8-IN-8 (Compound A11) is a Nav1.8 channel inhibitor. Nav1.8-IN-8 may prevent associated diseases mediated by sodium ion channels (NaV).
    Nav1.8-IN-8
Cat. No. Product Name / Synonyms Application Reactivity